$1.3 Billion AI in Diagnostics Industry Assessment 2020-2026 by Diagnosis Type, Component and Region
August 26, 2020 08:21 ET
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and...
bioAffinity Technologies Joins National Lung Cancer Roundtable
October 11, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer...
bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair
March 12, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 12, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide...
bioAffinity Technologies Selected as Finalist for Cancer Innovation Award
March 06, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 06, 2019 (GLOBE NEWSWIRE) -- Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics...
bioAffinity Technologies Announces Award of Canadian Patent
February 04, 2019 12:25 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the...
South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung
October 23, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is...
bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung
July 17, 2018 14:40 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 17, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an...
bioAffinity Technologies Joins Early Detection Research Network
March 01, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 01, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has been approved for membership in the Early Detection...
OTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference Participants
January 11, 2018 13:39 ET
|
OTraces, Inc.
SAN FRANCISCO and BALTIMORE, Jan. 11, 2018 (GLOBE NEWSWIRE) -- OTraces Inc., a Sykesville, Maryland-based cancer diagnostics company with a unique patented and patent-pending blood test which...
Zomedica Pharmaceuticals Corp. Enters into License and Supply Agreement with Celsee, Inc. for Cancer Liquid Biopsy Platform
December 21, 2017 06:55 ET
|
Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company,...